AU2019324134B2 - Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides - Google Patents
Antagonistic anti-tumor necrosis factor receptor superfamily polypeptidesInfo
- Publication number
- AU2019324134B2 AU2019324134B2 AU2019324134A AU2019324134A AU2019324134B2 AU 2019324134 B2 AU2019324134 B2 AU 2019324134B2 AU 2019324134 A AU2019324134 A AU 2019324134A AU 2019324134 A AU2019324134 A AU 2019324134A AU 2019324134 B2 AU2019324134 B2 AU 2019324134B2
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- amino acid
- antibody
- virus
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765284P | 2018-08-20 | 2018-08-20 | |
| US62/765,284 | 2018-08-20 | ||
| PCT/US2019/047330 WO2020041361A1 (en) | 2018-08-20 | 2019-08-20 | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026210856A Division AU2026210856A1 (en) | 2018-08-20 | 2026-08-01 | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019324134A1 AU2019324134A1 (en) | 2021-04-15 |
| AU2019324134B2 true AU2019324134B2 (en) | 2026-05-07 |
Family
ID=69591189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019324134A Active AU2019324134B2 (en) | 2018-08-20 | 2019-08-20 | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12624117B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3840782A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7713880B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260004528A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112955179A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019324134B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3109954A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020041361A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6367836B2 (ja) | 2013-02-07 | 2018-08-01 | ザ ジェネラル ホスピタル コーポレイション | T制御性細胞の増殖または枯渇方法 |
| DK3447075T3 (da) | 2015-05-15 | 2023-11-13 | Massachusetts Gen Hospital | Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien |
| AU2016286108B2 (en) | 2015-06-30 | 2021-03-11 | Pfizer Inc. | BTLA fusion protein agonists and uses thereof |
| WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| KR20250007678A (ko) | 2016-05-13 | 2025-01-14 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
| WO2020041361A1 (en) * | 2018-08-20 | 2020-02-27 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| EP3880711A4 (en) | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| WO2021231922A1 (en) * | 2020-05-14 | 2021-11-18 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| JP7895285B2 (ja) | 2020-06-12 | 2026-07-27 | ナンチン リーズ バイオラブス カンパニー,リミティド | Tnfr2に結合する抗体およびその用途 |
| IL299235A (en) * | 2020-07-02 | 2023-02-01 | Biolojic Design Ltd | Antibodies against (TNFR2) and their uses |
| CN112159818B (zh) * | 2020-08-20 | 2023-02-21 | 山东兴瑞生物科技有限公司 | 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法 |
| EP4281482A4 (en) * | 2021-01-21 | 2025-04-30 | The General Hospital Corporation | ANTAGONIST ANTIBODIES OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| US20250043015A1 (en) * | 2021-06-30 | 2025-02-06 | Shenghe (China) Biopharmaceutical Co., Ltd. | Anti-tnfr2 single domain antibody, and preparation method therefor and application thereof |
| CN116334768A (zh) * | 2022-07-14 | 2023-06-27 | 上海肽盛医药有限公司 | 一种结构多样的多肽库及其构建方法和应用 |
| WO2024219994A1 (ru) * | 2023-04-16 | 2024-10-24 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения |
| CN116650660B (zh) * | 2023-07-27 | 2023-11-03 | 上海偌妥生物科技有限公司 | 制备抗体偶联小分子药物的方法及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015145360A1 (en) * | 2014-03-24 | 2015-10-01 | Glennie Martin J | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| WO2017197331A2 (en) * | 2016-05-13 | 2017-11-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309418A (en) | 1980-03-25 | 1982-01-05 | Sloan-Kettering Research Institute For Cancer | Anti-tumor agent from human serum and process |
| SE8204382L (sv) | 1981-07-21 | 1983-01-22 | Hayashibara Biochem Lab | Sett att framstella malcellysfaktor och anvendning derav |
| US4457916A (en) | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5288852A (en) | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
| US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| DE3423234A1 (de) | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| US4677064A (en) | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| WO1986003751A2 (en) | 1984-12-21 | 1986-07-03 | Biogen N.V. | Purification, production and use of tumor necrosis factors |
| US4681760A (en) | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
| US5059530A (en) | 1985-09-30 | 1991-10-22 | Suntory Ltd. | Expression vector for human TNF |
| US5002876A (en) | 1986-09-22 | 1991-03-26 | Phillips Petroleum Company | Yeast production of human tumor necrosis factor |
| US4985241A (en) | 1986-11-21 | 1991-01-15 | Cetus Corporation | Therapeutic combination of free-radical scavenger and tumor necrosis factor |
| US4963354A (en) | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5215743A (en) | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
| US5370870A (en) | 1989-10-06 | 1994-12-06 | Genentech, Inc. | Method for protection against reactive oxygen species |
| US5283058A (en) | 1990-08-30 | 1994-02-01 | The General Hospital Corporation | Methods for inhibiting rejection of transplanted tissue |
| US5593698A (en) | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6984380B1 (en) | 1991-08-02 | 2006-01-10 | Denise L. Faustman | Treatment of diseases involving faulty MHC class I antigen complex presentation |
| WO1993002690A1 (en) | 1991-08-02 | 1993-02-18 | The General Hospital Corporation | Diagnosis and treatment of autoimmune diseases |
| US5139481A (en) | 1991-08-07 | 1992-08-18 | The General Hospital Corporation | Treatment for type II diabetes |
| US5843425A (en) | 1992-02-19 | 1998-12-01 | The General Hospital Corporation | Transplantation and graft-versus-host-disease |
| ES2168273T3 (es) | 1992-04-23 | 2002-06-16 | Sloan Kettering Inst Cancer | Ligando para el receptor c-kit y metodos de uso del mismo. |
| US5939532A (en) | 1993-09-07 | 1999-08-17 | Kyowa Hakko Kogyo Co., Ltd | Humanized antibodies to ganglioside GM2 |
| WO1994009137A1 (en) | 1992-10-15 | 1994-04-28 | Genentech, Inc. | Antibodies against type 2 tumor necrosis factor receptor |
| US5843452A (en) | 1992-11-09 | 1998-12-01 | Pharmagenesis, Inc. | Immunotherapy composition and method |
| US5560908A (en) | 1993-01-22 | 1996-10-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Therapeutic agent for NIDDM |
| US5728385A (en) | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
| US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| WO1997008328A1 (en) | 1995-08-30 | 1997-03-06 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Selective elimination of t cells that recognize specific preselected targets |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| US5874306A (en) | 1996-12-12 | 1999-02-23 | The Regents Of The University Of California | Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells |
| AU6241698A (en) | 1997-01-21 | 1998-08-07 | Human Genome Sciences, Inc. | Tace-like and matrilysin-like polypeptides |
| WO1999029343A1 (en) | 1997-12-09 | 1999-06-17 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
| US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6284879B1 (en) | 1998-04-16 | 2001-09-04 | The General Hospital Corporation | Transport associated protein splice variants |
| US6165737A (en) | 1998-04-16 | 2000-12-26 | The University Of Texas System Board Of Regents | DNA fragmentation factor involved in apoptosis |
| EP1077724A2 (en) | 1998-04-17 | 2001-02-28 | The University Of Vermont | Methods and products related to metabolic interactions in disease |
| WO1999059632A1 (en) | 1998-05-18 | 1999-11-25 | Applied Research Systems Ars Holding N.V. | Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions |
| US7485293B1 (en) | 1999-02-18 | 2009-02-03 | Faustman Denise L | Method for inhibiting transplant rejection |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| JP3589912B2 (ja) | 1999-09-03 | 2004-11-17 | 泰久 福井 | ホスファチジルイノシトール−3,4−二リン酸を認識するモノクローナル抗体 |
| US20010046489A1 (en) | 1999-12-06 | 2001-11-29 | Habener Joel E. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| WO2001044472A1 (en) | 1999-12-16 | 2001-06-21 | Amgen, Inc. | Tnfr/opg-like molecules and uses thereof |
| US6414218B1 (en) | 2000-01-18 | 2002-07-02 | The General Hospital Corporation | Mouse model for rheumatoid arthritis |
| AU2001266604A1 (en) | 2000-05-26 | 2001-12-11 | Smith Kline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| US20020160502A1 (en) | 2000-09-26 | 2002-10-31 | Roger Williams Hospital | Recombinant BCG vaccines for the prevention and treatment of cancer |
| US20040031066A9 (en) | 2001-01-18 | 2004-02-12 | Faustman Denise L. | Mouse model for rheumatoid arthritis |
| US7582313B2 (en) | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| JP4596916B2 (ja) | 2002-09-05 | 2010-12-15 | メディミューン,エルエルシー | Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法 |
| CN1771055A (zh) * | 2002-09-05 | 2006-05-10 | 免疫医疗公司 | 通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法 |
| US20040229785A1 (en) | 2002-11-15 | 2004-11-18 | Denise Faustman | Screening methods to identify treatments for autoimmune disease |
| US7510877B2 (en) | 2003-09-26 | 2009-03-31 | The Regents Of The University Of Michigan | Hematopoietic stem cell identification and isolation |
| JPWO2005035578A1 (ja) | 2003-10-09 | 2007-11-22 | 協和醗酵工業株式会社 | ガングリオシドgm2に特異的に結合する抗体組成物 |
| EP1707627B1 (en) | 2003-12-25 | 2012-11-14 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic anti-CD40 antibody mutant |
| US8563308B2 (en) | 2004-03-10 | 2013-10-22 | The Rockefeller University | Culture-expanded T suppressor cells and methods of use thereof |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| CN101084014A (zh) | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
| US20080102054A1 (en) | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| CA2605253C (en) | 2005-04-11 | 2017-06-13 | Yale University | Selective modulation of tumour necrosis factor receptors in therapy |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP2107115A1 (en) | 2007-01-24 | 2009-10-07 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2 |
| JP2010531138A (ja) | 2007-06-13 | 2010-09-24 | ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー | 制御性t細胞ならびに同製造および使用方法 |
| US8900816B2 (en) | 2007-07-19 | 2014-12-02 | Duke University | Assay for anti-EGFRvIII antibodies |
| WO2009129538A2 (en) | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| JP5822822B2 (ja) | 2009-04-17 | 2015-11-24 | ニューヨーク ユニバーシティ | Tnfファミリー受容体を標的とし、tnf作用を拮抗するペプチド、その組成物、方法および使用 |
| WO2010124262A1 (en) | 2009-04-24 | 2010-10-28 | Allostera Pharma Inc. | Methods of identification of allosteramers and uses thereof |
| KR20120005460A (ko) | 2009-04-28 | 2012-01-16 | 베링거 인겔하임 인터내셔날 게엠베하 | Pkc-세타 억제제를 사용하는 면역학적 장애의 생체외 치료 |
| US8530392B2 (en) | 2009-05-13 | 2013-09-10 | Shionogi & Co., Ltd. | Test agent for visceral obesity and use thereof |
| MX2012004029A (es) | 2009-10-07 | 2012-05-08 | Macrogenics Inc | Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso. |
| WO2011107989A1 (en) | 2010-03-01 | 2011-09-09 | Lostam Biopharmaceuticals Ltd | Improved therapeutic antibodies against flagellated pseudomonas aeruginosa |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20130064831A1 (en) | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| KR101871008B1 (ko) | 2010-09-16 | 2018-06-25 | 발리오팜 아게 | 항-huTNFR1 항체 |
| WO2012058137A2 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Methods for diversifying antibodies, antibodies derived therefrom and uses thereof |
| EP2468764A1 (en) | 2010-12-24 | 2012-06-27 | Rijksuniversiteit te Groningen | TNF family ligand variants |
| WO2012122464A1 (en) | 2011-03-10 | 2012-09-13 | New York University | Methods and compositions for modulating tnf/tnfr signaling |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| WO2013165982A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-human cytomegalvirus antibodies and use thereof |
| US9531457B2 (en) | 2012-07-18 | 2016-12-27 | Kyocera Corporation | Interference management of device-to-device communication in a cellular communication system |
| JP6367836B2 (ja) | 2013-02-07 | 2018-08-01 | ザ ジェネラル ホスピタル コーポレイション | T制御性細胞の増殖または枯渇方法 |
| EP3180087B1 (en) | 2014-08-12 | 2019-03-13 | Alligator Bioscience AB | Combination therapies with anti cd40 antibodies |
| US9172855B1 (en) | 2014-08-28 | 2015-10-27 | Avigilon Corporation | Pendant housing for a camera |
| WO2016094309A1 (en) * | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
| DK3447075T3 (da) | 2015-05-15 | 2023-11-13 | Massachusetts Gen Hospital | Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien |
| WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| CA3004830A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| SG10201912556VA (en) * | 2016-07-20 | 2020-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CA3033665A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| IL307684B2 (en) * | 2016-09-29 | 2025-04-01 | Amgen Inc | Low viscosity antigen binding proteins and methods for preparing them |
| JP7054209B2 (ja) | 2016-11-21 | 2022-04-13 | 国立研究開発法人医薬基盤・健康・栄養研究所 | エピトープ均質化抗体パネル、ならびにその作製方法および利用 |
| AU2017384528A1 (en) * | 2016-12-19 | 2019-07-04 | Ichnos Sciences SA | Novel TNFR agonists and uses thereof |
| WO2019094559A2 (en) | 2017-11-09 | 2019-05-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| WO2020041361A1 (en) | 2018-08-20 | 2020-02-27 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| EP3880711A4 (en) | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| WO2020193718A1 (en) | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| WO2021231922A1 (en) | 2020-05-14 | 2021-11-18 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
-
2019
- 2019-08-20 WO PCT/US2019/047330 patent/WO2020041361A1/en not_active Ceased
- 2019-08-20 JP JP2021509865A patent/JP7713880B2/ja active Active
- 2019-08-20 EP EP19852179.1A patent/EP3840782A4/en active Pending
- 2019-08-20 US US17/269,315 patent/US12624117B2/en active Active
- 2019-08-20 CA CA3109954A patent/CA3109954A1/en active Pending
- 2019-08-20 CN CN201980068984.8A patent/CN112955179A/zh active Pending
- 2019-08-20 KR KR1020257040897A patent/KR20260004528A/ko active Pending
- 2019-08-20 KR KR1020217008246A patent/KR20210061350A/ko not_active Ceased
- 2019-08-20 AU AU2019324134A patent/AU2019324134B2/en active Active
-
2023
- 2023-01-09 US US18/152,078 patent/US20230295326A1/en not_active Abandoned
-
2025
- 2025-03-19 JP JP2025044879A patent/JP2025118591A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015145360A1 (en) * | 2014-03-24 | 2015-10-01 | Glennie Martin J | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| WO2017197331A2 (en) * | 2016-05-13 | 2017-11-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
Non-Patent Citations (1)
| Title |
|---|
| HEATHER TORREY ET AL: "Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs", SCIENCE SIGNALING, vol. 10, no. 462, 17 January 2017 (2017-01-17), pages eaaf8608, * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020041361A1 (en) | 2020-02-27 |
| CN112955179A (zh) | 2021-06-11 |
| CA3109954A1 (en) | 2020-02-27 |
| US20210340268A1 (en) | 2021-11-04 |
| JP7713880B2 (ja) | 2025-07-28 |
| KR20260004528A (ko) | 2026-01-08 |
| EP3840782A1 (en) | 2021-06-30 |
| JP2025118591A (ja) | 2025-08-13 |
| JP2021534757A (ja) | 2021-12-16 |
| KR20210061350A (ko) | 2021-05-27 |
| EP3840782A4 (en) | 2022-06-08 |
| US12624117B2 (en) | 2026-05-12 |
| AU2019324134A1 (en) | 2021-04-15 |
| US20230295326A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250066494A1 (en) | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides | |
| US20230295326A1 (en) | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides | |
| US20240270860A1 (en) | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | |
| US12152082B2 (en) | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | |
| US20220348645A1 (en) | Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells | |
| US20240101693A1 (en) | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | |
| WO2025122817A1 (en) | Antagonistic cd40 antibodies | |
| HK40101997A (en) | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | |
| HK1261204B (en) | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |